Status:
COMPLETED
Can Austrian Lung Specialists' Assessments of Lung Cancer Screening be Influenced by a Fact Box?"
Lead Sponsor:
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Conditions:
Lung Cancer
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Lung cancer is the most frequently dianosed cancer worldwide. To date, no screening method has been able to establish itself as routinely recommended by the guidelines. In this prospective study with ...
Detailed Description
The topic of lung cancer screening is highly topical and relevant in that this cancer is the most frequently diagnosed worldwide and has the highest mortality among malignancies. To date, no screening...
Eligibility Criteria
Inclusion
- Members of the Austrian Society of Pneumology (ÖGP) with a completed pulmonary subject and members of the Austrian Radiological Society (ÖRG), Society for Medical Radiology and Nuclear Medicine with a completed subject.
Exclusion
- Non members of the Austrian Society of Pneumology (ÖGP)
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
973 Patients enrolled
Trial Details
Trial ID
NCT04819477
Start Date
May 1 2021
End Date
October 30 2021
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
Vienna, Austria, 1160